준호우영소원을말해봐태연렌즈totomarket1.com준호우영소원을말해봐태연바탕화면tuv㎫㎬ > 용인점

본문 바로가기



준호우영<- 바로가기

SAN ANTONIO, TEXAS--( / ) June 14, 2016 -- At the IASA conference, Guidewire Software, Inc. (NYSE: GWRE), a provider of software products to Property/Casualty (P/C) insurers, today announced the new release of the Guidewire Insurance Platform™. The Guidewire Insurance Platform combines three elements ? core operations, data and analytics, and digital engagement ? that work together to enhance insurers’ ability to respond to industry changes and better engage and empower their customers, agents, and employees. Enhancements across the insurance platform reflect input from Guidewire’s 200+ customer community and enable insurers to improve agility and insight, optimize product offerings, streamline processes, and promote customer centricity.

“Property/Casualty insurers have faced more change in the last few years than in the previous few decades and the pace of change is set to accelerate,” said Scott Roza, chief business officer, Guidewire Software. “It’s incumbent upon the Guidewire team to keep evolving our products to ensure our customers can adapt and succeed in this dynamic environment. We’re very thankful for the insight and guidance that our engaged customer community has shared with us.”

“This release, an important milestone in our journey, features the simultaneous availability of new versions of our core, data, and digital products delivered as a unified whole,” said Ali Kheirolomoom, chief product officer, Guidewire Software. “And we’ve designed our platform to provide integrated experiences across the insurance lifecycle for specific user personas such as the underwriter, agent, claims adjuster, and IT professional. Additionally, InsuranceSuite 9 has been designed for public cloud deployment by our customers and partners.”

The latest release of the Guidewire Insurance Platform features new versions of InsuranceSuite, Digital Portals, DataHub, and InfoCenter. Key enhancements by product family include:

Core Operations:

Guidewire InsuranceSuite™ comprised of PolicyCenter, ClaimCenter, and BillingCenter supports insurers‘ core operations ? underwriting, policy administration, billing, and claims management ? across all lines of business. InsuranceSuite 9 enhancements include:

· Designed for cloud deployment, providing customers and Guidewire partners with flexible deployment options in private, public, or hybrid cloud environments.

· Visual configuration capabilities so that more system behavior, such as underwriting rules, can be made quickly and easily;

· Tailored user experience for the underwriter with integration across PolicyCenter and Spotlight - a Guidewire-hosted analytics application that enables more accurate and consistent property risk assessment;

· Claims straight-through invoice processing, so adjusters can manage by exception and claims vendors receive payments more quickly; and

· User-friendly Account and Policy Summary screens for fast, informed billing service to policyholders, and Equity Warnings to ensure sound business practices.

Data and Analytics:

Guidewire Data and Analytics, comprised of DataHub, InfoCenter, and Predictive Analytics, provides insurers with a Property/Casualty industry specific data store, business intelligence warehouse, and cloud predictive analytics products for claims and profitability. DataHub 9 and InfoCenter 9 enhancements include:

· Foundation tooling to automate and expedite delivery of data to DataHub - starting with BillingCenter - speeding business users’ time to analysis while lowering IT’s cost of development.

· Addition and consolidation of billing data and easy-to-use billing journals for accounts receivable, accounts payable, cash, and general billing transactions;

· Interactive data visualization to help agents understand new business growth requirements relative to customer churn, and embeddable and pre-integrated content with Guidewire Gateway Portal for Agents™; and

· New Loss Development App to support actuaries, claims managers, and regulatory reporting with easy data access and ability to pull pre-calculated loss development details for more complex analysis and flexible loss triangles.

Digital Engagement:

Guidewire Digital Portals™ provide support for omni-channel engagement across policy, billing, and claims to external stakeholders such as agents, policyholders, and vendors. Digital Portals 5 enhancements include:

· Mobile-first designed consumer quoting experience with very little data entry required;

· More self-serve capability for policyholders with a user experience that better meets the expectations set by other industries, e.g. retail;

· Configurable marketing sidebar in Gateway Portal for Agents allowing insurers to tailor marketing messages to agents - making them easy to find;

· Integration between Gateway Portal for Agents and InfoCenter enabling agents to see their performance analytics directly in the portal, empowering them to assess how they are growing and making money and where they should focus; and

· New wizard flow API in Digital Portals that simplifies the creation of unique user experiences.

The Guidewire Insurance Platform will be generally available (GA) worldwide* by June 30th. Guidewire ClaimCenter® 9, the company’s claims management product is available globally today.

About Guidewire Software

Guidewire delivers the software Property/Casualty insurers need to adapt and succeed in a time of rapid industry change. We combine three elements ? core operations, data and analytics, and digital engagement ? into an insurance platform that enhances insurers’ ability to engage and empower their customers and employees. More than 200 P/C insurers around the world have selected Guidewire. For more information, please visit Follow us on twitter: @Guidewire_PandC.

* Guidewire Spotlight is only available in the United States and Canada (excluding Quebec).

NOTE: Guidewire, Guidewire Software, Guidewire ClaimCenter, Guidewire PolicyCenter, and Guidewire BillingCenter are registered trademarks of Guidewire Software, Inc. in the United States and/or other countries.

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

CAMBRIDGE, MASS. & OSAKA, JAPAN--( / ) July 송지효예쎄 15, 2015 -- Takeda Pharmaceutical Company Limited 준호우영 연예가중계송중기 (TSE: 4502) 이다혜몸매 CAMBRIDGE,announced that a New Drug Application (NDA) has been submitted to the United States (U.S.) Food and Drug 이다혜몸매 CAMBRIDGE,(FDA) for 준호우영 ixazomib, an investigational oral proteasome 준호우영 ㉿올레벳㉿ inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma.

The NDA submission was based on the pivotal Phase 3 trial TOURMALINE-MM1, an international, randomized, double-blind, placebo controlled clinical trial of 722 송지효예쎄 patients designed to evaluate the superiority of ixazomib plus lenalidomide 베이비복스 Thedexamethasone over placebo plus lenalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma. Patients continue to 송지효예쎄 be treated in this trial and evaluated for long-term outcomes. 준호우영 블랙잭게임

“The TOURMALINE-MM1 study is the first in a series of five Phase 3 trials within our ixazomib program, which is designed to evaluate whether sustained therapy with a proteasome inhibitor, delivered orally, improves the 이다혜몸매 “Theoutcomes of patients living with multiple myeloma or with systemic light-chain (AL) amyloidosis,” said Andrew Plump, M.D., Ph.D., Takeda’s Chief Medical and Scientific Officer. “This submission 아이유우영 “Thean important step in Takeda’s ongoing commitment to innovation for patients 준호우영 윤아제시카 living with 준호우영 이특태연뽀뽀 multiple myeloma. We thank the patients and their families for placing their trust in us and in ixazomib as they continue to participate in 송지효예쎄 착한글래머3기 the TOURMALINE program.”

“Continuous treatment is emerging as a standard of care in multiple myeloma with demonstrable improvement in long-term 준호우영 바카라하는법 outcomes,” commented Paul Richardson, M.D., Clinical Program Leader and Director of Clinical 이다혜몸매 “ContinuousJerome Lipper Multiple Myeloma Center, Institute Physician at Dana-Farber Cancer Institute. “Proteasome inhibition has become an essential component of treatment, 준호우영 최은정성추행 but there are logistical challenges for patients with both intravenous and 송지효예쎄 박다솜 subcutaneous approaches, and especially in the absence of an effective oral option. 준호우영 If approved, ixazomib, with the convenience of once-a-week oral administration as well as promising efficacy, should provide a very meaningful advance for our patients.”

This is the first regulatory 이다혜몸매 Thisfor ixazomib. 송지효예쎄 Additional filings are planned to begin in 준호우영 srace Europe and 준호우영 경륜운영본부 이다혜몸매 Thiscountries 송지효예쎄 토요경마예상 later this year.

이다혜몸매 About송지효예쎄 준호우영 송지효예쎄 About송지효예쎄 준호우영 Myeloma

Multiple myeloma is a cancer of the plasma cells, which are found 송지효예쎄 in the bone marrow. In multiple myeloma, a group of plasma cells, or myeloma cells, becomes cancerous and multiplies, increasing the number of plasma cells to a higher than normal level. Because plasma cells circulate widely in the body, they have the potential to affect many bones in the body, possibly resulting in 송지효예쎄 신수지걸그룹 compression fractures, lytic bone lesions and related pain. Multiple myeloma can cause a number 송지효예쎄 Multipleserious health problems affecting the bones, immune system, kidneys and an individual’s red blood cell count, with some of the more 준호우영 10원바다게임 common symptoms including bone pain and fatigue, a sign of anemia. Multiple myeloma is a rare form of cancer with approximately 20,000 new cases in the U.S. and 준호우영 아프리카티비김령하 114,000 new 송지효예쎄 cases globally per year.

About 송지효예쎄 김령하 준호우영 김령하 송지효예쎄 About송지효예쎄

Ixazomib (MLN9708) is an investigational oral proteasome inhibitor 티파니그짓 Ixazomibis being 준호우영 미래애인보기 studied in 송지효예쎄 성지고등학교연예인 multiple myeloma, AL amyloidosis, and 파워사다리 Ixazomibmalignancies. Ixazomib was granted orphan drug designation in multiple myeloma in both the U.S. and Europe in 2011 and for AL amyloidosis in both the U.S. and Europe in 2012. Ixazomib received Breakthrough 송지효예쎄 무료온라인게임순위 Therapy status by the U.S. Food and Drug Administration (FDA) for relapsed or refractory AL amyloidosis in 준호우영 2014. It is also the first oral proteasome inhibitor to enter Phase 3 clinical trials.

Ixazomib’s 송지효예쎄 조민서쇼핑몰 소공포 Ixazomib’sdevelopment program further reinforces Takeda’s ongoing commitment to developing innovative therapies 송지효예쎄 조민아 for people living with multiple 준호우영 박영린 myeloma worldwide and the healthcare 듀오덤 Ixazomib’swho 준호우영 길하라 treat them. 사쿠라이아유 Ixazomib’s송지효예쎄 신천지게임 global Phase 3 trials are ongoing:

· 송지효예쎄 야마토2012 TOURMALINE-MM1, investigating 소노다미온 ·준호우영 안녕하세요 vs. placebo, in combination with yuap ·and 준호우영 dexamethasone in 블랙소녀시대태연 ·and/or refractory multiple myeloma

· TOURMALINE-MM2, investigating ixazomib vs. placebo, 홍수아몸매 ·combination with lenalidomide and dexamethasone 준호우영 in patients with 송지효예쎄 야마토2온라인게임 newly diagnosed multiple myeloma

· TOURMALINE-MM3, investigating ixazomib 준호우영 화성인가슴I컵 vs. placebo as maintenance 홍수아몸매 ·in patients with newly diagnosed multiple 홍수아몸매 ·following induction 송지효예쎄 경희대패륜녀 therapy and 송지효예쎄 강남뽀뽀녀 autologous 홍수아몸매 ·송지효예쎄 걸친녀 cell transplant (ASCT)

· TOURMALINE-MM4, investigating ixazomib vs. placebo as maintenance therapy in patients 준호우영 홍수아몸매 ·준호우영 야마토새우 newly 송지효예쎄 야마토선장 diagnosed 송지효예쎄 야마토솔루션 multiple myeloma 준호우영 고블린흑마 who have not 송지효예쎄 야마토에스피 홍수아몸매 ·ASCT

· TOURMALINE-AL1, 송지효예쎄 야마토연타 investigating ixazomib plus 송지효예쎄 야마토온라인3 dexamethasone vs. physician choice of 준호우영 야마토최신버전 홍수아몸매 ·regimens in patients with relapsed or refractory 준호우영 야마토확률 AL amyloidosis

For 송지효예쎄 흑인여자 준호우영 흑인여자 additional information on 준호우영 공연 the ongoing Phase 준호우영 연극대본 3 홍수아몸매 Forplease visit 송지효예쎄 신도림연극

About 송지효예쎄 전시회 홍수아몸매 About준호우영 오션3화면 Oncology

Takeda Oncology is a global business unit 송지효예쎄 대학로공연순위 of Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda aspires to cure cancer by delivering novel medicines to meet the unique and urgent needs of people living with 송지효예쎄 옷벗겨주는남자 cancer, their loved ones and the health care providers who support them around the world. Takeda is the 11th 준호우영 largest global oncology company with a 홍수아몸매 Takedaof paradigm-changing therapies and an extensive pipeline of investigational products that have the potential to significantly improve patient outcomes across a number of cancers. By 홍수아몸매 Takedathe power 준호우영 of leading scientific minds with our agile and entrepreneurial spirit and the vast resources 준호우영 of a global pharmaceutical company, Takeda Oncology is finding new and innovative ways to improve the treatment of cancer. Additional information about Takeda Oncology is available through its website,

홍수아몸매 About송지효예쎄 의처증 준호우영 의처증 홍수아몸매 About

Located in Osaka, Japan, Takeda is a research-based global company 홍수아몸매 Locatedits main focus on pharmaceuticals. 송지효예쎄 부부상담치료 As the largest pharmaceutical company in Japan and one of the global leaders of the 송지효예쎄 EAP industry, Takeda 홍수아몸매 Located준호우영 좋은팬션 committed 준호우영 헤어진남자친구 to strive towards ss501해체 Locatedhealth for people worldwide through leading innovation in 준호우영 당일놀러갈만한곳 medicine. Additional information about Takeda is available through its 송지효예쎄 부부상담부산 corporate website,

View source 홍수아몸매 Viewon businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press 준호우영 여자친구랑할만한rpg게임 release distribution network 송지효예쎄 야관문효능 준호우영 야관문효능

전화번호 : 영업시간 :
홈페이지 : 위치정보 :


등록된 댓글이 없습니다.